ADULT OVER 18 YRS, 300 MG BD .
THE FOLLOWING POINTS SHOULD BE CONSIDERED WHEN INITIATING THERAPY WITH MARAVIROC:
TROPISM TESTING IS REQUIRED FOR THE APPROPRIATE USE OF MARAVIROC. USE OF MARAVIROC IS NOT RECOMMENDED IN PATIENTS WITH DUAL/MIXED OR CXCR4-TROPIC HIV-1 AS EFFICACY WAS NOT DEMONSTRATED IN A PHASE 2 STUDY OF THIS PATIENT GROUP.
THE SAFETY AND EFFICACY OF MARAVIROC HAVE NOT BEEN ESTABLISHED IN TREATMENT-NAΓVE ADULT PATIENTS OR PEDIATRIC PATIENTS.
THE RECOMMENDED DOSE OF MARAVIROC DIFFERS BASED ON CONCOMITANT MEDICATIONS DUE TO DRUG INTERACTIONS.
POTENT CYP3A INHIBITORS (WITH OR WITHOUT A CYP3A INDUCER) INCLUDING:
PROTEASE INHIBITORS (EXCEPT TIPRANAVIR/RITONAVIR) DELAVIRDINE
KETOCONAZOLE, ITRACONAZOLE, CLARITHROMYCIN
OTHER POTENT CYP3A INHIBITORS (E.G., NEFAZODONE, TELITHROMYCIN) - 150 MG TWICE DAILY
OTHER CONCOMITANT MEDICATIONS, INCLUDING TIPRANAVIR/RITONAVIR, NEVIRAPINE, ALL NRTIS AND ENFUVIRTIDE : 300 MG TWICE DAILY
POTENT CYP3A INDUCERS (WITHOUT A POTENT CYP3A INHIBITOR) INCLUDING:
EFAVIRENZ, RIFAMPIN, CARBAMAZEPINE, PHENOBARBITAL, AND PHENYTOIN : 600 MG TWICE DAILY